Draznin B, Ayalon D, Hoerer E, Oberman Z, Harell A, Ravid R, Laurian L
Acta Diabetol Lat. 1977 Jan-Apr;14(1-2):51-61. doi: 10.1007/BF02624663.
The effect of short-term treatment with diphenylhydantoin (DPH) on the insulin secretion patterns during OGTT and on the daily insulin profile was studied in obese patients. DPH treatment for 3 days with a dose of 300 mg/die (100 mg, 3 times daily) significantly decreased the insulin release after glucose ingestion, but did not alter the basal insulin level. No effect on the fasting glucose concentration as well as on the glucose profiles during OGTT was observed after short-term DPH treatment. A smaller decrease of plasma free fatty acid concentration during OGTT performed after DPH administration confirmed the inhibitory effect of the drug on insulin release. Short-term DPH treatment was also shown to decrease markedly the postpradial insulin release in obese patients. No difference was noted between plasma 11-OHCS and serum HGH concentrations during OGTT before and after DPH treatment. The possible therapeutic role of DPH in obesity is discussed.
研究了苯妥英（DPH）短期治疗对肥胖患者口服葡萄糖耐量试验（OGTT）期间胰岛素分泌模式及每日胰岛素曲线的影响。以300毫克/日（100毫克，每日3次）的剂量给予DPH治疗3天，可显著降低葡萄糖摄入后的胰岛素释放，但不改变基础胰岛素水平。短期DPH治疗后，未观察到对空腹血糖浓度以及OGTT期间血糖曲线的影响。DPH给药后进行的OGTT期间，血浆游离脂肪酸浓度的下降幅度较小，证实了该药物对胰岛素释放的抑制作用。短期DPH治疗还显示可显著降低肥胖患者餐后胰岛素释放。DPH治疗前后OGTT期间血浆11-羟皮质类固醇（11-OHCS）和血清生长激素（HGH）浓度之间未发现差异。讨论了DPH在肥胖症中的可能治疗作用。
